Biosimilar drugs are having an increased presence in conversations about the aHUS therapeutic drug landscape. Here's why they're of interest.
Atypical HUS Relapse: A Family View. Second in a 3-part series about how one family experienced the challenges of having this rare disease recur after many years 'off treatment.
Generium launches the first biosimilar drug to eculizumab, known as Elizaria. What is a biosimilar? What might this biosimilar mean for aHUS patients, and the physicians who treat them? The aHUS Alliance looks at the science behind biosimilars, as well as issues such as drug cost and access for those affected by the rare disease atypical HUS.
Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?
Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.
Dr Errol Gottlich and Professor Mignon McCulloch Resilience, fortitude and determination. These characteristics describe the South African doctor treating patients within a complex and…
Earlier this year the alliance began a watch on trials announced which relate to treatment of aHUS. Click here for the…